FindTrial
Sign In

The effect of remimazolam based total intravenous anesthesia on postoperative nausea and vomiting in gynecologic laparoscopic surgery – double-blinded, prospective, non-inferiority, randomized controlled study

The effect of remimazolam based total intravenous anesthesia on postoperative nausea and vomiting in gynecologic laparoscopic surgery – double-blinded, prospective, non-inferiority, randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0006765
Enrollment
138
Registered
2021-11-19
Start date
2021-07-12
Completion date
Unknown
Last updated
2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : - remimazolam group: intravenous continuous infusion by 12 mg/kg/hr for anesthetic induction and followed intravenous continuous infusion by 1 mg/kg/hr for anesthetic maintenance. Stop at the

Sponsors

Inje University Haeundae Paik Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: laparoscopic gynecologic surgery general anesthesia

Exclusion criteria

Exclusion criteria: pregnant allergic history(propofol or any benzodiazepine drugs) American society of Anesthesiology Physical stauts(ASA PS) >3

Design outcomes

Primary

MeasureTime frame
the incidence of moderate to severe postoperative nausea and vomiting—

Secondary

MeasureTime frame
Degree of postoperative nausea and vomiting—

Countries

Korea, Republic of

Contacts

Public ContactMyoung Jin Ko

Inje University Haeundae Paik Hospital

masterane@gmail.com+82-51-797-0423

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026